Comparison of Hematocrit Levels in Infant Heart Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00006183|
Recruitment Status : Completed
First Posted : August 22, 2000
Last Update Posted : July 29, 2016
|Condition or disease||Intervention/treatment||Phase|
|Cardiovascular Diseases Heart Diseases Heart Defects, Congenital Transposition of Great Vessels||Procedure: Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits Procedure: Thoracic Surgery||Phase 3|
The optimal degree of hemodilution during profoundly hypothermic CPB remains controversial, and widely dissimilar hemodilution studies have evolved at centers that perform infant cardiac surgery. HCT, a measurement of the volume of red blood cells, is of interest in cardiopulmonary bypass. Higher HCT levels expose individuals to the risks of microvascular occlusion (blockage in the small blood vessels), while lower HCT levels may critically limit oxygen delivery to the brain and other organs. Preliminary research suggests that higher HCT levels provide superior brain and myocardial protection, but there have not been any studies that report on outcomes after usage of higher versus lower HCT levels.
In this single-center, prospective, randomized study, hemodilution to a HCT level of 35% versus 25% will be compared with respect to neurodevelopmental outcome and early postoperative course in infants with congenital heart disease. The first aim of this study will test the hypothesis that hemodilution to a HCT level of 35%, compared to a level of 25%, will be associated with superior central nervous system protection. The primary outcome variable will be developmental outcome at age 1 year, assessed using the Bayley Scales of Infant Development. Secondary outcome variables include the following: 1) tissue release of S-100 protein as a measure of cerebral cellular injury; 2) cerebral hemodynamics and oxygenation, determined by near infrared spectroscopy (NIRS); 3) intrinsic cerebral vasoregulation, measured by NIRS and transcranial Doppler; and 4) at age 1 year, neurologic examination, the MacArthur inventory, and structural and volumetric findings of magnetic resonance imaging (MRI).
The second aim of this study will test the hypothesis that hemodilution to a HCT level of 35%, compared to a level of 25%, will be associated with better early postoperative cardiovascular status. The primary outcome measure will be serum lactate levels 1 hour after the surgery. Secondary outcome measures will include the following: 1) the duration of postoperative endotracheal intubation, ICU stay, and hospital stay; 2) serum lactate levels; 3) the PaO2/FiO2 ratio; 4) levels of circulating pro-inflammatory cytokines; and 5) the percent change in total body water, estimated by bioelectrical impedance. The structure of the study will allow assessment of whether 1-year outcomes can be predicted by perioperative variables other than the HCT strategies. Through the use of novel techniques such as NIRS and volumetric MRI, the study may also provide insight into mechanisms by which HCT and other perioperative variables affect the brain. The information obtained from this study should be broadly generalized to infants with other forms of congenital heart disease undergoing early repair and should have substantial impact on clinical practice.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Hematocrit Strategy in Infant Heart Surgery|
|Study Start Date :||July 2000|
|Actual Primary Completion Date :||July 2005|
|Actual Study Completion Date :||July 2005|
- Serum lactate levels (measured 1 hour after surgery)
- Developmental outcome (measured by Bayley Scales of Infant Development at age 1 year)
- Duration of postoperative endotracheal intubation, ICU stay, and hospital stay
- PaO2/FiO2 ratio
- Levels of circulating pro-inflammatory cytokines
- Percent change in total body water, as estimated by bioelectrical impedance (measured 1 hour after surgery)
- Tissue release of S-100 protein as a measure of cerebral cellular injury
- Cerebral hemodynamics and oxygenation, as determined by near infrared spectroscopy (NIRS)
- Intrinsic cerebral vasoregulation, as measured by NIRS and transcranial Doppler
- Neurologic factors, as determined by neurologic examination, the MacArthur inventory, and structural and volumetric findings of MRI (measured at age 1 year)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00006183
|United States, Massachusetts|
|Boston, Massachusetts, United States, 02115|
|Study Chair:||Jane W. Newburger, MD, MPH||Children's Hospital Medical Center, Cincinnati|